Liver Transplantation Following Life-threatening Abdominal Trauma: A Case Series of 5 Patients at a Single Institution

Managing traumatic liver injury (TLI) is always challenging and demands precise clinical judgment. Currently, treatment of TLI in most circumstances is non-operative; however, surgical therapy might be required for severe TLI, particularly those that result in extensive blood loss. In the current institutional study carried out from June 1995 to April 2017, we describe our experience with 5 patients who received an orthotopic liver transplant for severe TLI. One patient passed away postoperatively from cerebral edema; 1 patient died of renal failure 4 years after the liver transplantation, and 3 patients are still alive. Based on our experience, we conclude that in patients with TLI, especially those with uncontrollable bleeding or those who develop liver failure, liver transplantation should be taken into consideration.     

真武汤联合厄贝沙坦、美托洛尔治疗心肾综合征患者的临床效果

目的研究真武汤联合厄贝沙坦、美托洛尔治疗心肾综合征患者的临床效果。方法选取2016年5月至2019年5月我院收治的100例心肾综合征患者为研究对象,根据入院顺序随机将其分为对照组与观察组,各50例。对照组给予厄贝沙坦、美托洛尔治疗,观察组在对照组基础上给予真武汤治疗。比较两组的临床疗效。结果治疗后,两组患者的Scr、BUN、BNP水平均降低,且观察组低于对照组(P<0.05)。观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的CRP、IL-18、TNF-α水平均降低,且观察组低于对照组(P<0.05)。治疗后,两组的ET-1水平均降低,NO水平均升高,观察组优于对照组(P<0.05)。结论真武汤联合厄贝沙坦、美托洛尔治疗心肾综合征患者具有显著的协同作用,且能够降低患者的血清炎症因子水平,值得临床推广应用。     

水陆地黄汤联合盐酸贝那普利对气阴两虚夹瘀型糖尿病肾病氧化应激及临床指标的影响

目的:观察水陆地黄汤对气阴两虚夹瘀型糖尿病肾病氧化应激及临床指标的影响。方法:60例气阴两虚夹瘀型糖尿病肾病患者随机分为对照组与联合组,每组30例,对照组给予盐酸贝那普利片10 mg,1次/d,联合组在对照组基础上加服水陆地黄汤,1剂/d。治疗12周后观察两组氧化应激指标:谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)及临床指标:空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、尿微量白蛋白(mALB)、24 h尿蛋白定量(24 hU-PQ)、肾小球滤过率(eGFR)的变化及临床症状的改善。结果:联合组治疗总有效率为90.0%,与对照组56.7%比较,差异有统计学意义(P<0.05);治疗后联合组MDA较治疗前均降低(P<0.05),SOD、GSH-Px均高于治疗前(P<0.05),与对照组比较,差异有统计学意义(P<0.05);联合组FPG、2 hPG、HbA1c、mALB、24 hU-PQ、eGFR较治疗前均降低(P<0.01)。结论:水陆地黄汤联合盐酸贝那普利可改善气阴两虚夹瘀型糖尿病肾病氧化应激状态,明显缓解临床症状,延缓病程进展。     

三仁汤对脾胃湿热型大鼠NLRP3、Caspase-1蛋白的影响＊

目的 探究三仁汤对脾胃湿热型大鼠NLRP3、Caspase-1蛋白的调控及胃黏膜细胞焦亡的影响。方法 将50只雄性SD大鼠随机分为正常组、模型组、三仁汤高、中、低剂量组，每组各10只。根据前期的研究方法，利用高脂、高糖、湿热的条件，复制脾胃湿热证的模型，给予三仁汤干预，高、中、低剂量分别为16.4 g/kg，8.2 g/kg，4.1 g/kg。HE染色观察胃黏膜病理变化，免疫印迹法检测大鼠胃黏膜细胞NLRP3、Caspase-1蛋白的表达。结果HE结果显示，三仁汤高、中、低剂量组均对胃黏膜细胞焦亡有所改善。免疫印迹的结果显示模型组大鼠NLRP3和Caspase-1高表达，三仁汤高、中、低剂量组下调NLRP3和Caspase-1蛋白的表达，具有统计学差异（P < 0.05）。结论 三仁汤可能通过降低脾胃湿热大鼠的NLRP3、Caspase-1蛋白的表达，减少胃粘膜细胞焦亡，抑制胃粘膜炎症的爆发，从而防治脾胃湿热证模型大鼠，为临床治疗脾胃湿热证的胃痛提供了理论依据。     

滋肾调冲汤治疗黄体功能不足性月经失调的临床效果分析

目的:探讨滋肾调冲汤治疗黄体功能不足性月经失调的临床价值。方法:对2016年6月-2018年7月本院收治的73例黄体功能不足性月经失调患者的临床资料进行回顾性分析,按照治疗方式的不同分为研究组(37例)与对照组(36例)。对照组患者给予戊酸雌二醇及醋酸甲羟孕酮片进行治疗,研究组患者给予中药滋肾调冲汤,对比两组患者治疗后的疗效观察指标。结果:治疗后,经t检验,两组患者的临床证候积分及各项症状积分明显低于治疗前(P<0.05);研究组患者的临床证候积分及各项症状积分明显低于对照组(P<0.05)。两组患者的高温相评分(Hightemperature Phase Score,HPS)、黄体中期孕酮水平均明显高于治疗前,激素水平低于治疗前(P<0.05);研究组患者的HPS评分、黄体中期孕酮及激素水平均明显高于对照组,激素水平低于对照组(P<0.05)。结论:滋肾调冲汤治疗黄体功能不足性月经失调的疗效显著,可以有效延长黄体期时间,改善临床症状及体征,对促进患者快速康复有积极意义。     

Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis

The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in comparison between CHD with BSS patients (Group A) and healthy subjects (Group C), 59 significantly differential metabolites in the positive mode and 18 significantly differential metabolites in the negative mode. The metabolite constituents in the plasma of 30 CHD with BSS patients before (group A) and after 30 days of treatment (Group B), and 20 healthy subjects (Group C) were analyzed using LC-Q-TOF/MS and GC-MS. Based on multivariate statistical analysis (PCA, PLS-DA and OPLS-DA), we determined 69 differential metabolites. The levels of hemorheology indexes were significantly down-regulated after treatment. Metabolic pathway attribution analysis showed that lipid metabolism, amino acid metabolism and bile acid metabolism pathways are involved. Our study identifies the metabolic networks of CHD and demonstrates the efficacy of this metabolomics approach to systematically study the therapeutic effect of XFZYC on CHD.     

Clinical efficacy and safety of modified Sijunzi decoction for the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis

Background:Ulcerative colitis (UC) is a chronic non-specific intestinal inflammatory disease with unknown etiology. In recent years, the global incidence has been increasing. Sijunzi decoction (SJZD) is a traditional Chinese medicine that has been used for treatment of other diseases in previous studies as it has no side effects and it has a pharmacological effect in gastrointestinal function, immune system, ulcers, and tissue repair.Methods:PubMed, Embase, Cochrane Library, GeenMedical, China National Knowledge Infrastructure, Chinese Sci-tech Journals full-text Database, Chinese Biomedical Database, and Chinese Science Citation Database were searched to screen the related literatures of “ulcerative colitis” and “Jiawei Sijunzi decoction”. The research data extracted from above studies was analyzed by Review Manager 5.3 and Stata14.2 software.Results:This systematic review and meta-analysis will evaluate the efficacy and safety of Jiawei SJZD in the treatment of UC and provide effective evidence for clinical use.Conclusion:In this study, the published evidence of modified SJZD in the treatment of UC was systematically summarized and evaluated, so that it can be better applied in clinic.INPLASY registration number:INPLASY2020100102     

《伤寒论》和《温病条辨》中汤剂煎煮终点的判断

煎煮时间对于保证中药汤剂临床疗效和中成药质量起着至关重要的作用，从古至今，中药汤剂煎煮终点的判断一直是困扰人们的技术难题。对中医药典籍《伤寒论》和《温病条辨》中汤剂的煎煮时间及其煎煮终点的判断经验进行了整理，发现其具有一定的规律，认为影响煎煮时间的因素主要有病证、方剂功效、药物药性、药材性状等；通过对其总结，并结合现代研究成果初步阐明传统中药汤剂煎煮终点的判断方法，以期能为中药汤剂煎煮时间及现代中药制剂的提取工艺寻求合理的科学依据，为保证中药汤剂临床疗效和中药制剂的质量提供理论基础。